Bracco Expands VUEWAY MRI Contrast Agent into Mexico
Event summary
- Bracco's VUEWAY® injection (gadopiclenol) received approval from Mexico's COFEPRIS in September 2025 for use in adults and children aged 2+.
- The contrast agent offers effective imaging at lower gadolinium doses, aligning with clinical guidelines.
- VUEWAY is now approved in 38 countries with over 4 million patient doses administered globally.
- Bracco collaborates with Guerbet on manufacturing and R&D for gadopiclenol, each owning separate IP.
The big picture
Bracco's expansion into Mexico with VUEWAY reinforces its strategy to globalize lower-dose MRI contrast solutions. The approval comes amid growing radiology society emphasis on minimizing gadolinium exposure, positioning Bracco to capture demand in both developed and emerging markets. With over €2 billion in annual revenue and 9% of turnover invested in R&D, the company is doubling down on diagnostic imaging innovation.
What we're watching
- Regulatory Momentum
- Whether Bracco can sustain approval momentum in additional emerging markets.
- Market Penetration
- The pace at which VUEWAY adoption accelerates in Latin America compared to established regions.
- Competitive Dynamics
- How Guerbet's parallel commercialization of gadopiclenol under a different brand impacts market share.
Related topics